New chemical Entities (NCE)
New chemical Entities (NCE) for the Treatment of Pain
Though pain affects million of people it continues to be untreated, undertreated or inappropriately treated. This continues to occur in spite of the knowledge that without timely, appropriately tailored care, pain can weaken the immune system and slow discovery from disease or injury. Persistent pain leads to needless suffering and lost productivity.
Chronic pain is not only emotionally and physically debilitating for the patients, it also places a tremendous burden on families and caregivers. The undertreatment of pain contributes to excessive healthcare costs and lost work productivity.
Grünenthal´s interest in pain research started in 1962, when Kurt Flick designed a simple molecule containing the essential structural elements of morphine to be a potent analgesic. This prediction was clinically confirmed and today this compound – tramadol – is one of the leading centrally acting analgesics.
Forty years after the discovery of tramadol, research at Grünenthal is still focused on the search for even better analgesics.
The aim is to deliver improved medications either in cases where insufficient treatment options exist, or where improvements in efficacy or safety/tolerability would lead to an overall patient benefit in therapy.